HeXun Biosciences Co (ROCO:6986) Cash And Cash Equivalents : NT$201.0 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is HeXun Biosciences Co Cash And Cash Equivalents?

HeXun Biosciences Co's quarterly cash and cash equivalents declined from Dec. 2023 (NT$257.67 Mil) to Jun. 2024 (NT$205.84 Mil) but then stayed the same from Jun. 2024 (NT$205.84 Mil) to Dec. 2024 (NT$200.99 Mil).

HeXun Biosciences Co's annual cash and cash equivalents increased from Dec. 2022 (NT$119.74 Mil) to Dec. 2023 (NT$257.67 Mil) but then declined from Dec. 2023 (NT$257.67 Mil) to Dec. 2024 (NT$200.99 Mil).

HeXun Biosciences Co Cash And Cash Equivalents Historical Data

The historical data trend for HeXun Biosciences Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeXun Biosciences Co Cash And Cash Equivalents Chart

HeXun Biosciences Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

71.69

85.03

119.74

257.67

200.99

HeXun Biosciences Co Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial			119.74	220.56	257.67	205.84	200.99

HeXun Biosciences Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

HeXun Biosciences Co (ROCO:6986) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

HeXun Biosciences Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of HeXun Biosciences Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

HeXun Biosciences Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HeXun Biosciences Co Ltd (ROCO:6986) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN

Website

https://www.hexunbio.com

HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.

HeXun Biosciences Co Headlines

No Headlines